I have neither a Facebook account nor a Twitter account, but thanks A2Z.

Wait, What, did you just say no crying or whining? What great epiphany did you just have? Looking forward to IND...hopeful. I guess you and I agree now A2Z.

and it still seems possible management could blow it, as they enrich themselves and use disgusting rhetoric.

Hoping to grab some shares when it goes under a dollar.

Your answer is read between the lines? really. Sorry not buying "read between the lines" as DD. One more try, Do you have any actual due diligence to back up your statement or is it a false statement. I think all board readers know the answer.

Show us a press release that says IND is off the table this year. Please we are very interested in that. If your going to make a statement like that show us your due diligence, or you won't be taken seriously.

You already said it, “don’t invest more than you can loose”. Those who have played this right have free shares now. Wish that was me. I am holding.

I have been harassing Investor Relations again. In our last communication they wrote:

"We are publishing a press release in the next few days that will summarize what we have been working on over the past several months."

So at least we will get some info on where we are with the IND soon.

I like the line "you chose this investment". I like to take responsibility of my own actions. If PMCB fails, I am blaming no-one but myself for the loss. No victim complex here. Patience Pink Patience.

What is your opinion of PharmaCyte’s therapy for pancreatic cancer (Cell-in-a-Box® + low doses of ifosfamide)?

Dr. Manuel Hidalgo: “The data from the two earlier trials is very interesting and showed great promise many years ago when compared to the standard of care at the time – gemcitabine alone. Mechanistically the therapy makes a lot of sense. Patients with locally advanced, inoperable pancreatic cancer have a grim prognosis, and PharmaCyte’s therapy is worth exploring in this setting.

“I am excited about this new approach that has the potential to change the way solid tumors are treated far beyond tumors in the pancreas.”

Great post, my thoughts exactly.

I agree, the company's silence does not necessarily mean there is a problem. Maybe there is, maybe there isn't, but silence is not telling us that.

Assumed, got it, thanks

"Right now I’m praying that they can fix problem with their last project on cells dividing thru testing for contamination"

What problem are you referring to? I missed this. Please post your DD stating what the problem is. TIA

That’s right, Cara is further advanced with their treatment and they still don’t communicate with their shareholders. That was my point. They are more advanced and they are acting just like PMCB. Thank you for helping me clarify my point.

As I wait for results on Cara Therapeutics Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus, I noted the date of there last update on this trial. It was January 2. I guess I should start posting on their message board that they are a scam and demand updates.

Obviously my point is these things take a great amount of time. You don't discover a breakthrough and hand it to the FDA. If you are looking for a lottery ticket with PMCB then I would sell. The actual process of getting this to market and making a profit is in its early stages but it has started. I do not plan on crying like a baby every step of the way. If I think it smells bad I will sell my shares and let everyone here know why.

As of now I am excited because they are working to file a perfect IND, not one that gets kicked back to them with a bunch of test requests. The company is focused like a laser on this trial. If the trial is successful the company will get massive investment dollars from big Pharma at the very least.

I am holding and checking for the next PR. I was told by another investor on this board that only companies with promise have Golems( to use 1234's term). Be glad they are here, it means we have something promising. GO PMCB!

I received a duplicate IR response.

That is sad, i hope that is not true.

"You give me the millions they had and one year after a pre ind I could get an IND in."

I am truly impressed with you Fraum if that is the case. You should have been the CEO the whole time. What are we thinking having all these business and medical professionals on our board when all we really needed was you. They may have made mistakes you would not have made, but I think you underestimating the difficulty of filing an IND for a cell encapsulation application.

I could file an IND tomorrow if it doesn't have to be good. That is not the point. It does need to be good, it needs to be perfect, because the longer this drags along, the more dilution we experience. Lets get it filed and in perfect form. We can't half a%$ an IND just to file it.

I think I will wait a month before I call. Let them work now.

Here you go 1234jklm, Office Number: 917.595.2850, let us know what they say. Tia

It's riff raff. A rift raft is a boat. I get answers from IR as well when I actually contact them. I do not think the 15th of April is relevant, but we will get a press release soon good or bad.

Are you referring to the future osmotic challenges by vasopressin neurons?

I not looking for any ihub issues

A2Z, i am not understanding your use of the term "Dream Date", and how that is directed at me. Peace to you brother.

A rabble rouser gets people fired up to act. I don't do that. I get fired up on my own and act.

I am certainly a long here. I don't remember ever posting a date. I have only seen one date posted by a long here and that date is April 15. This date was posted with no due diligence to support it. I know you are frustrated with the company, but don't take it out on your fellow posters.

My opinion is one of two things is going on:

1. There was a problem with the final tests, or they are working out some technical difficulties. This would be bad for the pps, but the company has a master cell bank in place and they do not need to start at the very beginning again. It would be a costly delay however because it could lead to the company selling more shares.

or

2. They are having the IND paperwork previewed by everyone involved and this takes time. They have one shot at this and it needs to be done perfectly. As shareholders this is what we want them to do. I do not want the company to rush anything because of a few rabble rousers on a message board.

I try to form my opinions on press releases and credible due diligence that I have seen with my own eyes. I do not consider others opinions wether they agree with mine or not. "It's just business Sonny its not personal"

There is some hard work being put in today. PMCB

First , let me commend you, that post actually was understandable. It is PharmaCyte’s responsibility to file IND, butt Austrianovas’ work is crucial to the content. Nice try though.

Is it possible they are still doing paperwork? In there response to me a couple weeks ago they said that they and Austrianova are working on IND. They can't pull an all nighter like some college kid to finish the paper. It needs to be exactly right.

I think you are right Bio.

IND is filed and they will be gone like rubbish in a dumpster>

Very educational post JK! Thank You

Efood, If they are not planning on filing the IND soon then they should release an update now that we are in the 2nd quarter of the year. Time for a status report for shareholders.

I much enjoyed the article. A foreshadow perhaps.

Thank You Mind1 for the great dd you sent me regarding PharmaCyte Biotech, advice heeded.

PharmaCyte Discusses Pancreatic Cancer Clinical Trial with Medpace’s Medical Monitor Dr. Lyon Gleich

https://ir.pharmacytebiotech.com/press-releases/detail/188/pharmacyte-discusses-pancreatic-cancer-clinical-trial-with

"Hidalgo where is works isn't even" ?

PharmaCyte Biotech Engages cGMP Validation to Assist in Preparation of IND for Pancreatic Cancer Trial

https://ir.pharmacytebiotech.com/press-releases/detail/187/pharmacyte-biotech-engages-cgmp-validation-to-assist-in

"Dr. Hidalgo is unquestionably a leader in oncology worldwide, and PharmaCyte Biotech is extremely fortunate to land Dr. Hidalgo as the Principal Investigator for what could be its landmark clinical trial in pancreatic cancer."

From The interview with World Renowned Oncologist DR Hidalgo discussing our treatment:

What interested you in accepting the extremely important role of Principal Investigator in such an important clinical trial for those patients who need an option beyond Abraxane® + gemcitabine or FOLFIRINOX?

Dr. Manuel Hidalgo: “As investigators we are always interested in and excited about new approaches to treating pancreatic cancer—the third most deadly cancer and soon to become the second most deadly. With the strong rationale and the preliminary data from the two earlier trials, PharmaCyte’s therapy has the potential to make a significant difference.

“When we try a new treatment we really hope it will be safe and effective for patients. I became attracted to PharmaCyte’s study because I think it has such potential.”